INS and type 2 diabetes mellitus: Increasing evidence indicates that abnormal sphingolipid metabolism is deeply involved in the metabolic reprogramming of diabetes (especially T2DM) by interfering with insulin signaling, inducing chronic inflammation, destroying mitochondrial function, and promoting β-cell apoptosis (99).